A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Gastroesophageal Junction
調査の概要
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Min Shi
- 電話番号:020-62787736
- メール:nfyyshimin@163.com
研究連絡先のバックアップ
- 名前:Chunlin Wang
- 電話番号:020-62787735
- メール:wangchunl03@163.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510515
- 募集
- Nanfang Hospital
-
コンタクト:
- Min Shi
- 電話番号:020-62787736
- メール:nfyyshimin@163.com
-
コンタクト:
- Chunlin Wang
- 電話番号:020-62787735
- メール:wangchunl03@163.com
-
主任研究者:
- Min Shi
-
副調査官:
- Chunlin Wang
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- The local advanced stage confirmed by histopathology is unresectable, recurrent or metastatic Adenocarcinoma of stomach and gastroesophageal junction.
- After receiving first-line treatment, the disease progressed or intolerable adverse reactions occurred.
- At least one measurable lesion or evaluable lesion (according to RECIST 1.1 standard);
- Patients agreed to provide blood samples and previously stored tumor tissue samples for tumor microenvironment detection.
- Age ≥18 years old and ≤75 years old.
- The ECOG score is 0 or 1.
- The estimated survival time is ≥3 months.
- Within 7 days before entering the group, the laboratory test value met the chemotherapy standard.
- Within 28 days before enrollment, women of childbearing age must confirm that the serum pregnancy test is negative and agree to adopt effective contraceptive measures during the study drug use and within 6 months after the last administration.
- Patients voluntarily joined the study, signed informed consent, and were able to comply with the visit and related procedures stipulated in the plan.
Exclusion Criteria:
- Participate in other intervention clinical studies at the same time (unless participating in observation studies or being in the follow-up stage of intervention studies), and have received second-line treatment.
- have received antibody therapy of PD-1, PD-L1, PD-L2, CTLA4, CD137 or any other antibody or drug therapy with t cell co-stimulation or immune checkpoint pathway as specific target.
- It is known to be allergic to any monoclonal antibody or adjuvant.
- Received Chinese patent medicines with anti-tumor indications or drugs with immunoregulatory effects (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration.
- Having undergone major surgery within 4 weeks before the first administration or expecting to undergo surgery during the study treatment.
- Receive live attenuated vaccine within 4 weeks before the first administration or during the planned study treatment.
- Received transplantation of solid organs or blood system.
- Active, known or suspected autoimmune diseases or related medical history in the past 2 years (vitiligo, psoriasis, alopecia or Graves' disease that does not require systematic treatment in the past 2 years, hypothyroidism that only requires thyroid hormone replacement therapy, and type I diabetes patients who only need insulin replacement therapy can enter Group).
- Immunosuppressive drugs have been used within 4 weeks before the first administration, excluding local glucocorticoid by nasal spray, inhalation or other routes or systemic glucocorticoid with physiological dose (i.e., prednisone or other glucocorticoid with equivalent dose not exceeding 10mg/ day), or hormone used due to allergy.
- Known history of primary immunodeficiency disease.
- Known history of active tuberculosis. 12 known to have a history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive).
13. after regular antihypertensive treatment, the blood pressure still cannot fall to the normal range (systolic blood pressure > >140mmHg, diastolic blood pressure > >90mmHg).
14. ≥II grade ii coronary heart disease and arrhythmia (including QTc interval prolongation > >450ms for men and > >470ms for women).
15. Symptomatic congestive heart failure (new york Heart Association Grade II-IV) or symptomatic or poorly controlled arrhythmia.
16. before the first administration, there was toxicity caused by previous anti-tumor treatment that did not recover to grade 0 or grade 1 of the national cancer institute general adverse event terminology version 4.03 (NCI ctcae version 4.03) (excluding alopecia, fatigue and asymptomatic laboratory abnormalities).
17. abnormal coagulation function (INR > 1.5 uln, aptt > 1.5 uln), with bleeding tendency.
18. It is known that symptomatic central nervous system metastasis exists. 19. Diagnosed as other malignant tumors within 5 years before the first administration, excluding basal cell carcinoma of skin, squamous cell carcinoma of skin and carcinoma in situ after radical resection.
20. Active infections requiring treatment or systemic anti-infective drugs used within 7 days before the first administration.
21. acute or chronic active hepatitis b: HBV viral load ≥500 copies /ml 22. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the study.
23. It is known that there are mental diseases or drug abuse situations that may affect the compliance with the test requirements.
24. Acute or chronic active hepatitis C: HCV antibody is positive. 25. Pregnant or lactating women. 26. There are medical histories, diseases, treatments or abnormal laboratory results that may interfere with the test results and prevent the subjects from participating in the study, or the researchers think that participating in the study is not in the best interests of the subjects.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Carelizumab Combined With Irinotecan and Apatinib
Second-line treatment of advanced gastric cancer with three-drug regimen(Carelizumab Combined With Irinotecan and Apatinib )
|
Three-drug regimen was used in second-line treatment of Advanced gastric cancer
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Suvival time(OS)
時間枠:Up to 24 months
|
The time from randomization to death due to any reason.
For those who have lost follow-up before death, the last follow-up time is usually calculated as the time of death.
|
Up to 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Progress Free Survival time(PFS)
時間枠:Up to 24 months
|
The time from randomization to the first occurrence of disease progression or death from any cause.
|
Up to 24 months
|
objective response rate(ORR)
時間枠:Up to 24 months
|
Refers to the proportion of patients whose tumors have shrunk to a certain amount and kept for a certain time, including CR and PR cases
|
Up to 24 months
|
duration of response (DoR)
時間枠:Up to 24 months
|
It is the curative effect evaluation index of tumor reaction, which refers to the time from the first evaluation of complete remission (CR) or partial remission (PR) to the first evaluation of disease progression (PD) or death from any cause
|
Up to 24 months
|
Disease control rate(DCR)
時間枠:Up to 24 months
|
The proportion of patients whose tumors have shrunk or remained stable for a certain period of time, including cases of complete remission (CR), partial remission (PR) and stable (SD)
|
Up to 24 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Safety and tolerability
時間枠:Up to 24 months
|
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v4.03
|
Up to 24 months
|
協力者と研究者
捜査官
- 主任研究者:Min Shi、Oncology department of Nanfang hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NFEC-2020-024
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
胃癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ